(1) SNP will reduce the occurrence of psychomimetic side effects during exposure to low]dose ketamine; (2) SNP will reduce the ketamine]induced increase in blood pressure and cardiac output; (3) SNP is without effect on ketamine]induced pain…
ID
Bron
Verkorte titel
Aandoening
Psychomimetic side effects ketamine
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
psychomimetic side effects evaluated by Bowdle and Bond & Lader.
Achtergrond van het onderzoek
The aim of this study is to evaluate whether the NO donor SNP prevents the occurrence of psychomimetic side effects without affecting ketamine induced analgesia.
Doel van het onderzoek
(1) SNP will reduce the occurrence of psychomimetic side effects during exposure to low]dose ketamine;
(2) SNP will reduce the ketamine]induced increase in blood pressure and cardiac output;
(3) SNP is without effect on ketamine]induced pain relief;
(4) SNP is effective in reducing negative effects in both S]ketamine and RS]ketamine treated subjects.
Onderzoeksopzet
1 hr of SNP adminstration 3 hrs of ketamine adminsitration in three concentrations. Psychomimetic side effects evaluated by questionaire will be evaluated at 15 min. intervals.
Analgesia will be evaluated at 15 min. intervals.
arterial samples will be obtained per protocol at intervals used for pharmacokinetic studies.
Onderzoeksproduct en/of interventie
Part 1: Sodium nitroprusside(SNP) or placebo will be administered intravenously started 60 minutes prior to intravenous administration of ketamine, and will be terminated when the ketamine infusion is ended. S-ketamine will be administered one hour 10mg/h, one hour 20mg/h, and one hour 40mg/h. R,S-ketamine will be administered one hour 20mg/h, one hour 40mg/h, and one hour 80mg/h.
Part 2: Ketamine (S-or R,S) will be administered intravenously 50mg/h and will be terminated after SNP is given for one hour. Concomitantly placebo infusion will be started, after one hour the placebo infusion will be replaced by SNP for one hour. (Single blinded).
Publiek
Department of Anesthesiology,
P.O. Box 9600
Albert Dahan
Albinusdreef 2
Leiden 2300 RC
The Netherlands
+31 (0)71 5262301
a.dahan@lumc.nl
Wetenschappelijk
Department of Anesthesiology,
P.O. Box 9600
Albert Dahan
Albinusdreef 2
Leiden 2300 RC
The Netherlands
+31 (0)71 5262301
a.dahan@lumc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Male subjects, aged 18]34 years with a body mass index < 30 kg/m2
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
Severe medical disease including hypertension, liver/renal disease, neurological disorders, diaphragmatic hernia/pyrosis; (history of) psychiatric or neurological disease; allergy to study medication; (history of) illicit drug abuse/alcoholism.
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL5211 |
NTR-old | NTR5359 |
Ander register | NL52444.058.15 : P15.049 |